Anavex Life Sciences Corp (AVXL)

[12x]

Thanks for sharing the P4 trial experience. It's not clear to me the difference between a before and post-approval confirmatory P3 (if there is even such a thing p3 not p4). ChatGPT seems to think so, EMA is unique in that regard and leans towards post-approval confirmatory P3.

The difference and likelihood of a confirmatory Phase 3 trial before or after Marketing Authorization Application (MAA) approval for blarcamesine depend on regulatory pathways and circumstances:

1. Confirmatory Phase 3 Before MAA Approval
Difference:

This would mean that regulatory agencies (e.g., EMA, FDA) require additional Phase 3 data to verify efficacy, safety, or both prior to approving blarcamesine for marketing.
The MAA would likely be delayed until the trial is completed and results are analyzed.
This often happens when the primary data submitted in the initial Phase 2/3 trials is deemed insufficient to meet regulatory requirements.
Likelihood:

Unlikely for EMA since the MAA has already been accepted, suggesting the EMA deemed the existing data sufficient for consideration. However, they could potentially ask for additional trials if concerns arise during the review process.
More Likely for other regulators (e.g., FDA, TGA, CFDA) that require at least two robust Phase 3 trials as part of their standard approval process for new Alzheimer's drugs. This depends on their evaluation of the current data.
2. Confirmatory Phase 3 After MAA Approval
Difference:

If the EMA approves the drug conditionally, it may mandate a confirmatory Phase 3 trial as part of the post-approval commitments.
The drug can still be marketed during this confirmatory trial, allowing patients access to treatment while additional data is collected.
This type of Phase 3 trial is designed to confirm efficacy and safety on a broader scale, ensuring real-world validation of the drug's performance.
Likelihood:

High for EMA conditional approval since the trial can confirm long-term benefits or address unanswered questions from earlier studies.
This is a common approach in the EU when early data is promising but not yet definitive (e.g., trials with smaller sample sizes or higher dropout rates).
Key Considerations:
Confirmatory Phase 3 Before MAA Approval:
Higher regulatory burden; delays market entry; increases development cost and risk.
Could signal regulators have concerns about data robustness.
Confirmatory Phase 3 After MAA Approval:
Balances timely market access with the need for additional evidence.
Indicates regulators have confidence in existing data but want longer-term or broader validation.
Conclusion:
The confirmatory Phase 3 after MAA approval is more likely for EMA due to the accepted MAA, making it the preferred pathway if conditional approval is granted.
A confirmatory Phase 3 before MAA approval could occur if regulators like the FDA or others demand additional trials as part of their review process. However, this would delay market access significantly.